CDK4 and carcinoma: While all HR+ patients receive adjuvant endocrine therapy, the addition of the PARP inhibitor olaparib or the CDK4/6 inhibitors abemaciclib or ribociclib is recommended only for intermediate- to high-risk carcinomas.